Dance Pharmaceuticals

Aerami Therapeutics, formerly known as Dance Pharmaceuticals, is a clinical-stage biopharmaceutical company specializing in the development of inhaled therapies for severe chronic diseases. The company leverages its proprietary Afina platform, a smart, breath-actuated vibrating mesh nebulizer designed to deliver precise, high-dose medications directly to the lungs with minimal effort from the patient. Its lead candidate, AER-901, is an inhaled formulation of imatinib currently in Phase 2 clinical trials for the treatment of pulmonary arterial hypertension (PAH). Originally founded to develop inhaled insulin (Dance 501), the company rebranded and shifted its strategic focus toward orphan lung diseases and other high-unmet-need respiratory conditions.